Twist Bioscience Company (NASDAQ:TWST) on Monday posted first-quarter 2026 outcomes of a lack of 50 cents per share, in line with the Wall Avenue expectations.
Gross sales reached $103.70 million, up 17% 12 months over 12 months, beating the consensus of $102.72 million, and the administration steering of $100 million-$101 million.
Adjusted EBITDA loss for the quarter was $13.4 million in comparison with a lack of $16.3 million a 12 months in the past.
The corporate shipped merchandise to roughly 2,538 prospects within the first quarter of 2026, in comparison with roughly 2,376 a 12 months in the past.
Twist shipped roughly 271,000 genes within the quarter in comparison with roughly 205,000 genes a 12 months in the past. The corporate stated greater than 50,000 genes had been manufactured for knowledge characterization.
Gross margin for the primary quarter of fiscal 2026 elevated to 52% in comparison with 48.3% a 12 months in the past.
As of December 31, 2025, the corporate had roughly $198 million in money, money equivalents and short-term investments.
“As we proceed by the 12 months and past, we stay centered on driving towards profitability with constant income progress, gross margins above 50% and disciplined spending to put money into scalable, sustainable progress alternatives whereas serving extra prospects, launching extra merchandise, and increasing our addressable markets,” stated Emily Leproust, CEO and co-founder of Twist Bioscience.
Outlook
Twist Bioscience raised fiscal 2026 gross sales steering from $425 million-$435 million to $435 million-$440 million versus the consensus of $431.39 million.
The steering expects the income improve versus prior steering to be usually balanced throughout DSPS and NGS.
Gross margin is predicted to be above 52% for fiscal 2026.
Twist reiterates its expectation to attain adjusted EBITDA breakeven for the fourth quarter of fiscal 2026.
The corporate expects second-quarter 2026 gross sales between $107-$108 million in comparison with the consensus of $105.84 million.
Analyst Take
William Blair wrote, “We stay assured within the long-term income progress trajectory of the corporate because it invests aggressively to penetrate a number of distinct markets, which collectively give the corporate a protracted runway of 20%-plus progress and a wide range of upside photographs on purpose.”
Analyst Matt Larew views the corporate’s efforts to be average investments because it scales into the FOTF and pushes towards adjusted EBITDA breakeven, making sense, and may broaden the attraction of the story if the corporate can execute towards that purpose.
William Blair charges the inventory Outperform.
TWST Worth Motion: Twist Bioscience shares had been up 10.59% at $45.42 on the time of publication on Monday, in accordance with Benzinga Professional knowledge.
Photograph by jittawit21 through Shutterstock